Patents by Inventor Allan S. Lau

Allan S. Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7132271
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2?-5? oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 7, 2006
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Patent number: 6864061
    Abstract: A method and cell line for screening test compounds for anti-inflammatory activity are disclosed. The cell line is a human cell line capable of producing a selected cytokine associated with an inflammatory response in humans, and transfected with (i) a vector containing DNA encoding a cytokine regulatory factor under the control of a first promoter, and (ii) a vector containing DNA encoding a detectable-marker protein, under the control of a second promoter which is responsive to cytokine induction. In the screening method, the cells are cultured under conditions of cytokine regulatory factor overexpression and cytokine induction. Addition of test compound that results in a diminution of the detectable-marker protein is evidence of anti-inflammatory activity.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: March 8, 2005
    Assignee: GeneTrol Biotherapeutics, Inc.
    Inventors: Allan S. Lau, Michael C. Kiefer
  • Patent number: 6855519
    Abstract: Methods for enhancing the production of interferons in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amounts of interferon can be recovered without conventional induction of interferon by virus.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: February 15, 2005
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Publication number: 20040219642
    Abstract: Methods for enhancing the production of interferons in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amounts of interferon can be recovered without conventional induction of interferon by virus.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 4, 2004
    Inventor: Allan S. Lau
  • Publication number: 20040157310
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2′-5′ oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Application
    Filed: November 24, 2003
    Publication date: August 12, 2004
    Inventor: Allan S. Lau
  • Patent number: 6686190
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2′-5′ oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: February 3, 2004
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Patent number: 6673591
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2′-5′ oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: January 6, 2004
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Publication number: 20030129162
    Abstract: Human cytokine mixtures produced by cytokine regulatory factor-overexpressing cells and methods of production are disclosed. The mixtures are prepared by culturing human cytokine-producing cells under conditions of cytokine regulatory factor overexpression, treating the cells to induce cytokine production, and isolating the mixtures of cytokines produced by the cells. Preferred compositions, for use in treating viral infection or cancer, include a mixture of human interferon &ggr; and either human interferon &agr; or human interferon &bgr;, in a mole ratio of between 2:1 to 1:100 interferon &ggr; to interferon &agr; or human interferon &bgr;.
    Type: Application
    Filed: September 11, 2002
    Publication date: July 10, 2003
    Inventors: Allan S. Lau, Winnie H. Wan, Laura Browning, Natalya Ossina
  • Patent number: 6489144
    Abstract: Methods for enhancing the production of interferon in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amounts of interferon can be recovered without conventional induction of interferon by virus.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: December 3, 2002
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Publication number: 20020150552
    Abstract: Human cytokine mixtures produced by cytokine regulatory factor-overexpressing cells and methods of production are disclosed. The mixtures are prepared by culturing human cytokine-producing cells under conditions of cytokine regulatory factor overexpression, treating the cells to induce cytokine production, and isolating the mixtures of cytokines produced by the cells.
    Type: Application
    Filed: September 11, 2001
    Publication date: October 17, 2002
    Inventors: Allan S. Lau, Winnie H. Wan, Laura Browning, Natalya Ossina
  • Publication number: 20020150541
    Abstract: Human cytokine mixtures produced by cytokine regulatory factor-overexpressing cells and methods of production are disclosed. The mixtures are prepared by culturing human cytokine-producing cells under conditions of cytokine regulatory factor overexpression, treating the cells to induce cytokine production, and isolating the mixtures of cytokines produced by the cells. Exemplary compositions include mixtures of human interferon &ggr; in combination with human interferon &agr; and/or human interferon &bgr;, and mixtures of human interferon &agr; and human interferon &bgr;. Also disclosed are therapeutic uses of the interferon compositions.
    Type: Application
    Filed: March 21, 2002
    Publication date: October 17, 2002
    Applicant: Gene Trol Biotherapeutics, Inc.
    Inventors: Allan S. Lau, Winnie H. Wan, Laura Browning, Natalya Ossina
  • Publication number: 20020123075
    Abstract: A method and cell line for screening test compounds for anti-inflammatory activity are disclosed. The cell line is a human cell line capable of producing a selected cytokine associated with an inflammatory response in humans, and transfected with (i) a vector containing DNA encoding a cytokine regulatory factor under the control of a first promoter, and (ii) a vector containing DNA encoding a detectable-marker protein, under the control of a second promoter which is responsive to cytokine induction. In the screening method, the cells are cultured under conditions of cytokine regulatory factor overexpression and cytokine induction. Addition of test compound that results in a diminution of the detectable-marker protein is evidence of anti-inflammatory activity.
    Type: Application
    Filed: September 13, 2001
    Publication date: September 5, 2002
    Inventors: Allan S. Lau, Michael C. Kiefer
  • Publication number: 20010055791
    Abstract: Methods for enhancing the production of interferons in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amounts of interferon can be recovered without conventional induction of interferon by virus.
    Type: Application
    Filed: July 16, 2001
    Publication date: December 27, 2001
    Inventor: Allan S. Lau
  • Publication number: 20010031859
    Abstract: The present invention relates to compositions and methods for enhanced cytokine production in human cell culture, particularly under conditions where apoptotic cell death is suppressed by expression of CrmA.
    Type: Application
    Filed: January 26, 2001
    Publication date: October 18, 2001
    Inventors: Allan S. Lau, Natalya Ossina, Kenneth Hoyt
  • Publication number: 20010001709
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2′-5′ oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Application
    Filed: December 13, 2000
    Publication date: May 24, 2001
    Inventor: Allan S. Lau
  • Publication number: 20010001290
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2′-5′ oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Application
    Filed: December 13, 2000
    Publication date: May 17, 2001
    Inventor: Allan S. Lau
  • Patent number: 6159712
    Abstract: Methods for enhancing the production of interferons in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amounts of interferon can be recovered without conventional induction of interferon by virus.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: December 12, 2000
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau
  • Patent number: 5976800
    Abstract: The invention provides for methods and compositions based on the expression of cellular levels of double-stranded RNA dependent kinase (PKR), an interferon-regulated gene, is used to enhance cancer cell death. The PKR gene is encoded by vectors, optionally containing specific promoters that are activated only in specific target cells. Cells producing PKR are treated with non-toxic, low doses of apoptosis-inducing agents, such as TNF-.alpha. or poly I:C, leading to programmed cell death without the use of conventional chemotherapeutic agents. Designing of recombinant viral vectors for gene therapy based on these expression systems for the treatment of human hepatitis B and C viruses, human papilloma virus, and other cancers and viral diseases is also taught.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: November 2, 1999
    Assignee: The Regents of the University of California
    Inventors: Allan S. Lau, Michael C. Yeung
  • Patent number: 5840565
    Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR), PKR-deficient cells are obtained by a) transfecting a parent cell line with a PKR antisense polynucleotide; b) unaided uptake into a cell line by culturing said cell line in the presence of a PKR antisense polynucleotide; c) transfection of a parent cell line with a PKR dominant negative mutant; or d) culturing a cell line in the presence of 2-aminopurine. In cell cultures deficient for PKR, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 24, 1998
    Assignee: The Regents of the University of California
    Inventor: Allan S. Lau